Hepatic disorders in chronic kidney disease

Nature Reviews Nephrology

Volumn 6, Issue 7, 2010, Pages 395-403

  Fabrizi, Fabrizio ^a   Messa, Piergiorgio ^a   Basile, Carlo ^b   Martin, Paul ^c  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b MIULLI GENERAL HOSPITAL   (Italy)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALLOPURINOL; AMIODARONE; ANABOLIC AGENT; ANTIVIRUS AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; COTRIMOXAZOLE; CYCLOSPORIN A; ENTECAVIR; ERYTHROMYCIN; INTERFERON; ISONIAZID; LAMIVUDINE; METHYLDOPA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; RIFAMPICIN; SULFONAMIDE; TELBIVUDINE; TENOFOVIR; TETRACYCLINE;

ALCOHOL LIVER DISEASE; BLOOD DISEASE; CHOLESTASIS; CHRONIC ALLOGRAFT NEPHROPATHY; CHRONIC GLOMERULONEPHRITIS; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CHRONIC LIVER DISEASE; DIABETES MELLITUS; DRUG DOSE INCREASE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HEPATITIS; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DONOR; KIDNEY TRANSPLANTATION; LIVER CELL DAMAGE; LIVER DISEASE; LIVER DYSFUNCTION; LIVER TOXICITY; LOW DRUG DOSE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEPSIS; SURVIVAL; VIREMIA; VIRUS REPLICATION; VIRUS TRANSMISSION; COMORBIDITY; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; MORTALITY; RENAL INSUFFICIENCY, CHRONIC;

ANTIVIRAL AGENTS; COMORBIDITY; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; KIDNEY TRANSPLANTATION; RENAL INSUFFICIENCY, CHRONIC;

EID: 77954242738     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2010.37     Document Type: Review

References (118)

1. Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of Hepatitis C in chronic kidney disease. Kidney Int. 73 (Suppl. 109), S1-S99 (2008).
2. Fabrizi, F. et al. Influence of hepatitis C virus (HCV) viraemia upon serum aminotransferase activity in chronic dialysis patients. Nephrol. Dial. Transplant. 12, 1394-1398 (1997).
3. Josselson, J., Kyser, B. A., Weir, M. R. & Sadler, J. H. Hepatitis B surface antigenemia in a chronic hemodialysis program: lack of influence on morbidity and mortality. Am. J. Kidney Dis. 6, 456-461 (1987).
4. Jha, R. et al. Hepatitis B associated liver disease in dialysis patients: role of vaccination. J. Nephrol. 6, 98-103 (1993).
5. Fabrizi, F. et al. Influence of hepatitis B virus viremia upon serum aminotransferase activity in dialysis population. Int. J. Artif. Organs 26, 1048-1055 (2003).
6. Fabrizi, F. et al. Gamma-glutamyltranspeptidase activity and viral hepatitis in dialysis population. Int. J. Artif. Organs 30, 6-15 (2007).
7. Fabrizi, F., Bunnapradist, S. & Martin, P. HBV infection in patients with end-stage renal disease. Semin. Liver Dis. 24 (Suppl. 1), 63-70 (2004). (Pubitemid 38738360)
8. Rivolta, E. et al. Prognostic significance of hepatitis B surface antigenemia in cadaveric renal transplant patients. Transplant. Proc. 19, 2153-2154 (1987).
9. Huang, C. C., Lai, M. K. & Fong, M. T. Hepatitis B liver disease in cyclosporine-treated renal allograft recipients. Transplantation 49, 540-544 (1990).
10. Flagg, G. L., Silberman, H., Takamoto, S. K. & Berne, T. V. The influence of hepatitis B infection on the outcome of renal allotransplantation. Transplant. Proc. 19, 2155-2158 (1987).
11. Mathurin, P. et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 29, 257-263 (1999).
12. Aroldi, A. et al. Natural history of hepatitis B and C in renal allograft recipients. Transplantation 79, 1132-1136 (2005). (Pubitemid 40664010)
13. Hiesse, C. et al. Impact of HBs antigenemia on long-term patient survival and causes of death after renal transplantation. Clin. Transplant. 46, 461-467 (1992).
14. Ahn, H. J. et al. Clinical outcome of renal transplantation in patients with positive pretransplant hepatitis B surface antigen. J. Med. Virol. 79, 1655-1663 (2007).
15. Fabrizi, F., Martin, P., Dixit, V., Kanwal, F. & Dulai, G. HBsAg seropositive status and survival after renal transplantation: meta-analysis of observational studies. Am. J. Transplant. 5, 2913-2921 (2005). (Pubitemid 43923952)
16. LaQuaglia, M. P. et al. Impact of hepatitis on renal transplantation. Transplantation 32, 504-507 (1981).
17. Chen, J. B., Hsieh, H., Hsu, K. T. & Chen, C. H. Impact of donor hepatitis B antigenemia on renal allograft in hepatitis B recipients. Transplant. Proc. 28, 1490-1492 (1996).
18. Taskapan, H., Oymak, O., Dogukan, A., Ozbakir, O. & Utas, C. Transformation of hepatitis B virus-related membranoproliferative glomerulonephritis to crescentic form. Clin. Nephrol. 54, 161-163 (2000).
19. Farza, H. et al. Hepatitis B surface antigen gene expression is regulated by sex steroids and glucocorticoids in transgenic mice. Proc. Natl Acad. Sci. USA 84, 1187-1191 (1987). (Pubitemid 17027317)
20. McMillan, J. S., Shaw, T., Angus, P. W. & Locarnini, S. A. Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro. Hepatology 22, 36-43 (1995).
21. Cote, P. J., Tennant, B. C., Baldwin, B., Korba, B. E. & Gerin, J. L. Modulation of WHV infection and disease with cyclosporine A and dexamethasone. International Symposium on Viral Hepatitis and Liver Disease (Houston, 1990).
22. Grotz, W. et al. Occurrence and management of hepatitis B virus reactivation following kidney transplantation. Clin. Nephrol 49, 385-388 (1998).
23. Fabrizi, F. et al. The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies. J. Viral Hepat. 14, 697-703 (2007).
24. Kalantar-Zadeh, K. et al. Hepatitis C virus and death risk in hemodialysis patients. J. Am. Soc. Nephrol. 18, 1584-1593 (2007).
25. Johnson, D. W. et al. Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia-Pacific countries: analysis of registry data. Nephrol. Dial. Transplant. 24, 1598-1603 (2009).
26. Fabrizi, F., Messa, P & Martin, P. Health-related quality of life in dialysis patients with HCV infection. Int. J. Artif. Organs 32, 473-481 (2009).
27. Afsar, B., Ozdemir, N. F., Sezer, S. & Haberal, M. Quality of life is not related with liver disease severity but with anemia, malnutrition, and depression in HCV-infected hemodialysis patients. Hemodial. Int. 13, 62-71 (2009).
28. Afsar, B., Elsurer, R., Sezer, S. & Ozdemir, N. F. Quality of life in hemodialysis patients: hepatitis C virus makes sense. Int. Urol. Nephrol. 41, 1011-1019 (2009).
29. Okuda, K. & Yokosuka, O. Natural history of chronic hepatitis C in patients on hemodialysis: case control study with 4-23 years of follow-up. World J. Gastroenterol. 10, 2209-2212 (2004).
30. Fabrizi, F., Martin, P., Dixit, V., Bunnapradist, S. & Dulai, G. Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies. Am. J. Transplant. 5, 1452-1461 (2005). (Pubitemid 40839438)
31. Wolffenbüttel, L., Poli, D. D., Manfro, R. C. & Goncalves, L. F. Cyclosporine pharmacokinetics in anti-HCV positive patients. Clin. Transplant. 18, 654-680 (2004).
32. Ali, M. K. et al. Donor hepatitis C virus status does not adversely affect short-term outcomes in HCV positive recipients in renal transplantation. Transplantation 66, 1694-1697 (1998).
33. Mandal, A. K. et al. Shorter waiting times for hepatitis C virus seropositive recipients of cadaveric renal allografts from hepatitis C virus seropositive donors. Clin. Transplant. 14, 391-396 (2000).
34. Morales, J. M. et al. Transplantation of kidneys from donors with hepatitis C antibody into recipients with pre-transplantation anti-HCV. Kidney Int. 47, 236-240 (1995).
35. Woodside, K. J. et al. Use of kidneys from hepatitis C seropositive donors shortens waitlist time but does not alter one-year outcome. Clin. Transplant. 17, 433-437 (2003).
36. Bucci, J. R. et al. Donor hepatitis C seropositivity: clinical correlates and effect on early graft and patient survival in adult cadaveric kidney transplantation. J. Am. Soc. Nephrol. 13, 2974-2982 (2002).
37. Abbott, K. C. et al. Hepatitis C and renal transplantation in the era of modern immunosuppression. J. Am. Soc. Nephrol. 14, 2908-2918 (2003).
38. Abbott, K. C. et al. The impact of transplantation with deceased donor hepatitis C-positive kidneys on survival in waitlisted long-term dialysis patients. Am. J. Transplant. 4, 2032-2037 (2004).
39. Abbott, K. C. et al. Impact of diabetes and hepatitis after kidney transplantation on patients who are affected by hepatitis C virus. J. Am. Soc. Nephrol. 15, 3166-3174 (2004).
40. Widell, A. et al. Hepatitis C superinfection in hepatitis C virus (HCV)-infected patients transplanted with an HCV-infected kidney. Transplantation 60, 642-647 (1995).
41. Schussler, T., Staffeld-Coit, C., Eason, J. & Nair, S. Severe hepatitis C infection in a renal transplant recipient following hepatitis C genotype mismatch transplant. Am. J. Transplant. 4, 1375-1378 (2004).
42. Natov, S. N. et al. Hepatitis C virus genotype does not affect patient survival among renal transplant candidates. The New England Organ Bank Hepatitis C Study Group. Kidney Int. 56, 700-706 (1999).
43. Lai, M. E. et al. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet 343, 388-390 (1994).
44. Marzano, A. et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig. Liver Dis. 39, 397-408 (2007).
45. Ben-Ari, Z., Broida, E., Kittai, Y., Chagnac, A. & Tur-Kaspa, R. An open-label study of lamivudine for chronic hepatitis B in six patients with chronic renal failure before and after kidney transplantation. Am. J. Gastroenterol. 95, 3579-3583 (2000).
46. Boyacioglu, S., Gür, G., Gürsoy, M. & Ozdemir, N. Lamivudine in renal transplant candidates with chronic hepatitis B infection. Transplant. Proc. 34, 2131-2132 (2002).
47. Lapinski, T. W., Flisiak, R., Jaroszewicz, J., Michalewicz, M. & Kowalczuc, O. Efficiency and safety of lamivudine therapy in patients with chronic HBV infection, dialysis or after kidney transplantation. World J. Gastroenterol. 11, 400-402 (2005).
48. Schmilovitz-Weiss, H., Melzer, E., Tur-Kaspa, R. & Ben-Ari, Z. Excellent outcome of lamivudine treatment in patients with chronic renal failure and hepatitis B virus infection. J. Clin. Gastroenterol. 37, 64-67 (2003).
49. Fontaine, H. et al. HBV genotypic resistance to lamivudine in kidney recipients and hemodialyzed patients. Transplantation 69, 2090-2094 (2000).
50. Fabrizi, F., Marzano, A., Martin, P. & Lampertico, P. Hepatitis B virus infection in the dialysis population: current perspectives. Int. J. Artif. Organs 31, 386-394 (2008).
51. Fabrizi, F., Dulai, G., Dixit, V., Bunnapradist, S. & Martin, P. Lamivudine for the treatment of hepatitis B virus-related liver disease after renal transplantation: meta-analysis of clinical trials. Transplantation 77, 859-864 (2004).
52. Zubkin, M. et al. Treatment of chronic hepatitis B with lamivudine in renal transplant recipients. Int. J. Artif. Organs 30, 308-314 (2007).
53. Viganò, M. et al. Long-term lamivudine monotherapy in renal transplant recipients with hepatitis B-related cirrhosis. Antivir. Ther. 10, 709-713 (2005).
54. Kamar, N. et al. Effects of long-term lamivudine therapy in renal-transplant patients. J. Clin. Virol. 31, 298-303 (2004).
55. Thabut, D. et al. Long-term therapy with lamivudine in renal transplant recipients with chronic hepatitis B. Eur. J. Gastroenterol. Hepatol. 16, 1367-1373 (2004).
56. de Silva, H. J., Herath, C. A. & Sheriff, M. H. Lamivudine therapy for hepatitis B infection in post-renal transplant patients: results after 36 months follow-up. Liver Int. 25, 1074-1075 (2005).
57. Chan, T. M. et al. Preemptive lamivudine therapy based on HBV DNA level in HBsAg positive kidney allograft recipients. Hepatology 36, 1246-1252 (2002).
58. Fontaine, H. et al. Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency. Transplantation 80, 1086-1092 (2005).
59. de Silva, H. J., Dassanayake, A. S., Manamperi, A. & de Silva, A. P. Treatment of lamivudine-resistant hepatitis B infection in postrenal transplant patients with adefovir dipivoxil: preliminary results. Transplant. Proc. 38, 3118-3120 (2006).
60. Kamar, N. et al. Renal side effects of adefovir in hepatitis B virus positive kidney allograft recipients. Clin. Nephrol. 71, 36-42 (2009).
61. Kamar, N. et al. Entecavir therapy for adefovirresistant hepatitis B virus infection in kidney and liver allograft recipients. Transplantation 86, 611-614 (2008).
62. Fabrizi, F., Dixit, V., Messa, P. & Martin, P. Interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials. J. Viral Hepat. 15, 79-88 (2008).
63. Russo, M. W., Goldsweig, C. D., Jacobson, I. M. & Brown, R. S. Jr. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am. J. Gastroenterol. 98, 1610-1615 (2003).
64. Pol, S. et al. Efficacy and tolerance of alpha-2b interferon therapy on HCV infection of hemodialyzed patients. Kidney Int. 47, 1412-1418 (1995).
65. Hanrotel, C. et al. Virological and histological responses to one-year alpha-interferon-2a in hemodialyzed patients with chronic hepatitis C. Nephron 88, 120-126 (2001).
66. Fernández, J. L., Rendo, P., del Pino, N. & Viola, L. A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV Infection. J. Viral Hepat. 4, 113-119 (1997).
67. Campistol, J. M. et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrol. Dial. Transplant. 14, 2704-2709 (1999).
68. Huraib, S., Iqbal, A., Tanimu, D. & Abdullah, A. Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic hepatitis C. Am. J. Nephrol. 21, 435-440 (2001).
69. Mahmoud, I. M. et al. Interferon therapy in hemodialysis patients with chronic hepatitis C: study of tolerance, efficacy and posttransplantation course. Nephron Clin. Pract. 100, c133-c139 (2005).
70. Rocha, C. M. et al. Efficacy and tolerance of interferon-alpha in the treatment of chronic hepatitis C in end-stage renal disease patients on hemodialysis. Liver Int. 26, 305-310 (2006).
71. Sporea, I. et al. Effect of alpha 2b interferon treatment in hemodialyzed patients with chronic hepatitis C. Rom. J. Gastroenterol. 10, 285-288 (2001).
72. Grgurevic, I. et al. Efficacy of interferon-alpha in the treatment of chronic hepatitis C in dialysis patients: two therapeutic protocols compared. Nephron Clin. Pract. 103, c8-c11 (2006).
73. Casanovas-Taltavull, T. et al. Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: results after transplantation. Am. J. Gastroenterol. 96, 1170-1177 (2001).
74. Degos, F. et al. The tolerance and efficacy of interferon-alpha in haemodialysis patients with HCV infection: a multicentre, prospective study. Nephrol. Dial. Transplant. 16, 1017-1023 (2001).
75. Fabrizi, F., Dixit, V., Messa, P. & Martin, P. Pegylated interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials. J. Med. Virol. (in press).
76. Covic, A. et al. Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodialysis patients: results from a large, multicenter audit. J. Nephrol. 19, 794-801 (2006).
77. Russo, M. W., Ghalib, R., Sigal, S. & Joshi, V. Randomized trial of pegylated interferon alpha-2b monotherapy in hemodialysis patients with chronic hepatitis C. Nephrol. Dial. Transplant. 21, 437-443 (2006).
78. Sporea, I. et al. Pegylated-interferon alpha 2a treatment for chronic hepatitis C in patients on chronic hemodialysis. World J. Gastroenterol. 12, 4191-4194 (2006).
79. Casanovas-Taltavull, T. et al. Preliminary results of treatment with pegylated interferon alpha2a for chronic hepatitis C virus in kidney transplant candidates on hemodialysis. Transplant. Proc. 39, 2125-2127 (2007).
80. Chan, T. M. et al. Pilot study of pegylated interferon-alpha 2a in dialysis patients with chronic hepatitis C virus infection. Nephrology 12, 11-17 (2007).
81. Amarapurkar, D. N., Patel, N. D. & Kirpalani, A. L. Monotherapy with peginterferon alpha-2b (12kDa) for chronic hepatitis C infection in patients undergoing haemodialysis. Trop. Gastroenterol. 28, 16-18 (2007).
82. Espinosa, M. et al. Anemia associated with pegylated interferon-alpha2a and alpha2b therapy in hemodialysis patients. Clin. Nephrol. 6, 366-373 (2007).
83. Liu, C. H. et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naïve dialysis patients with chronic hepatitis C: a randomised study. Gut 57, 525-530 (2008).
84. Akhan, S. C., Kalender, B. & Ruzgar, M. The response to pegylated interferon alpha 2a in haemodialysis patients with hepatitis C virus infection. Infection 36, 341-344 (2008).
85. Ayaz, C., Celen, M. K., Yuce, U. N. & Geyik, M. F. Efficacy and safety of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. World J. Gastroenterol. 14, 255-259 (2008).
86. Annicchiarico, B. E. & Siciliano, M. Pegylated interferon alpha-2b monotherapy for hemodialysis patients with chronic hepatitis C. Aliment. Pharmacol. Ther. 20, 123-124 (2004).
87. Kokoglu, O. F. et al. Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. J. Gastroenterol. Hepatol. 21, 575-580 (2006).
88. Sikole, A. et al. Treatment of hepatitis C in hemodialysis patients with pegylated interferon alpha-2a monotherapy. Ren. Fail. 29, 961-966 (2007).
89. Teta, D. et al. Pegylated interferon for the treatment of hepatitis C virus in haemodialysis patients. Nephrol. Dial. Transplant. 20, 991-993 (2005).
90. Kose, S., Gurkan, A., Akman, F., Kelesoglu, M. & Uner, U. Treatment of hepatitis C in hemodialysis patients using pegylated interferon alpha-2a in Turkey. J. Gastroenterol. 44, 353-358 (2009).
91. Dzekova, P. et al. Long-term follow up of sustained viral response after treatment of hepatitis C with pegylated interferon alpha-2a in hemodialysis patients. Int. J. Artif. Organs 32, 180-184 (2009).
92. Mousa, D. H. et al. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C. Transplant. Proc. 36, 1831-1834 (2004).
93. Bruchfeld, A., Ståhle, L., Andersson, J. & Schvarcz, R. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection-a pilot study. J. Viral Hepat. 8, 287-292 (2001).
94. Tan, A. C. et al. Safety of interferon and ribavirin therapy in hemodialysis patients with chronic hepatitis C: results of a pilot study [letter]. Nephrol. Dial. Transplant. 16, 193-195 (2001).
95. Rendina, M. et al. The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant. J. Hepatol. 46, 768-774 (2007).
96. Bruchfeld, A., Lindahl, K., Reichard, O., Carlsson, T. & Schvarcz, R. Pegylated interferon and ribavirin in hemodialysis patients. Nephrol. Dial. Transplant. 21, 1444-1445 (2006).
97. Van Leusen, R. et al. Pegylated interferon alfa-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C. Nephrol. Dial. Transplant. 23, 721-725 (2008).
98. Carriero, D. et al. Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin. Int. J. Artif. Organs 31, 295-302 (2008).
99. Hakim, W. et al. HCV response in patients with end stage renal disease treated with combination pegylated interferon alpha-2a and ribavirin. J. Clin. Gastroenterol. 43, 477-481 (2009).
100. Liu, C. H. et al. Pegylated interferon alpha-2a plus low-dose ribavirin for the retreatment of dialysis chronic hepatitis C patients who relapsed from prior interferon monotherapy. Gut 58, 314-316 (2009).
101. Schmitz, V. et al. Peginterferon alfa-2b plus ribavirin for the treatment of hepatitis C recurrence following combined liver and kidney transplantation. Ann. Transplant. 12, 22-27 (2007).
102. Bruchfeld, A., Lindahl, K., Schvarz, R. & Ståhle, L. Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. Ther. Drug Monit. 24, 701-708 (2002).
103. Rostaing, L. et al. Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. Nephron 74, 512-516 (1996). (Pubitemid 26364720)
104. Baid, S. et al. Acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy. Am. J. Transplant. 3, 74-78 (2003).
105. Sharma, R. K. et al. Chronic hepatitis C virus infection in renal transplant: treatment and outcome. Clin. Transplant. 20, 677-683 (2006).
106. Ozgür, O., Boyacioglu, S., Telatar, H. & Haberal, M. Recombinant alpha-interferon in renal allograft recipients with chronic hepatitis C. Nephrol. Dial. Transplant. 10, 2104-2106 (1995).
107. Thervet, E. et al. Low-dose recombinant leucocyte interferon-alpha treatment of hepatitis C viral infection in renal transplant recipients. A pilot study. Transplantation 58, 625-628 (1994).
108. Carbognin, S. J. et al. Acute renal allograft rejection following pegylated IFN-alpha treatment for chronic HCV in a repeat allograft recipients on hemodialysis: a case report. Am. J. Transplant. 6, 1746-1751 (2006).
109. Wéclawiak, H. et al. Alpha-interferon therapy for chronic hepatitis C may induce acute allograft rejection in kidney transplant patients with failed allografts. Nephrol. Dial. Transplant. 23, 1043-1047 (2008).
110. Pageaux, G. P. et al. Pegylated interferonalpha- based treatment for chronic hepatitis C in renal transplant recipients: an open pilot study. Transpl. Int. 22, 562-567 (2009).
111. Sperl, J., Petrasek, J., Spicak, J. & Viklicky, O. Acute rejection of non-functional allograft in kidney transplant recipients with hepatitis C treated with peginterferon-alpha 2a. J. Hepatol. 49, 461-462 (2008).
112. Toth, C. M. et al. Hepatitis C virus-associated fibrosing cholestatic hepatitis after renal transplantation: response to interferon alpha therapy. Transplantation 66, 1254-1258 (1998).
113. Risser, A., Donovan, D., Heintzman, J. & Page, T. NSAID prescribing precautions. Am. Fam. Physician 80, 1371-1378 (2009).
114. Myhre, E., Rugstad, H. E. & Hansen, T. Clinical pharmacokinetics of methyldopa. Clin. Pharmacokinet. 7, 221-233 (1982).
115. Pol, S. et al. Azathioprine hepatitis in kidney transplant recipients. A predisposing role of chronic viral hepatitis. Transplantation 61, 1774-1776 (1996).
116. Karamehic, J. et al. Hepatotoxicity of cyclosporine in patients with kidney transplants [Croatian]. Med. Arh. 53, 193-195 (1999).
117. Neff, G. W. et al. Consumption of dietary supplements in a liver transplant population. Liver Transpl. 10, 881-885 (2004).
118. Fong, T. L. et al. Hepatotoxicity due to hydroxycut: a case series. Am. J. Gastroenterol. doi:10.1038/ajg.2010.5.